Dashboard
Manage Tickers

LLY ELI LILLY & Co

NYSE lilly.com


$ 826.51 $ 14.22 (1.75 %)    

Wednesday, 15-Oct-2025 19:52:51 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 602.61 $ 4.22 (0.71 %)
DIA $ 463.04 $ 0.00 (0 %)
SPY $ 665.11 $ 2.94 (0.44 %)
TLT $ 90.76 $ -0.20 (-0.22 %)
GLD $ 387.41 $ 6.60 (1.73 %)
$ 826.57
$ 812.36
$ 826.00 x 1
$ 828.00 x 18
$ 808.58 - $ 830.19
$ 622.41 - $ 931.66
2,355,840
na
743.75B
$ 0.60
$ 53.90
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-01-2025 03-31-2025 10-Q
3 02-19-2025 12-31-2024 10-K
4 10-30-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 04-30-2024 03-31-2024 10-Q
7 02-21-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 04-27-2023 03-31-2023 10-Q
11 02-22-2023 12-31-2022 10-K
12 11-01-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 04-29-2022 03-31-2022 10-Q
15 02-23-2022 12-31-2021 10-K
16 10-27-2021 09-30-2021 10-Q
17 08-03-2021 06-30-2021 10-Q
18 04-30-2021 03-31-2021 10-Q
19 02-17-2021 12-31-2020 10-K
20 10-28-2020 09-30-2020 10-Q
21 07-31-2020 06-30-2020 10-Q
22 05-01-2020 03-31-2020 10-Q
23 02-19-2020 12-31-2019 10-K
24 10-25-2019 09-30-2019 10-Q
25 08-02-2019 06-30-2019 10-Q
26 05-02-2019 03-31-2019 10-Q
27 02-19-2019 12-31-2018 10-K
28 11-06-2018 09-30-2018 10-Q
29 07-25-2018 06-30-2018 10-Q
30 04-27-2018 03-31-2018 10-Q
31 02-20-2018 12-31-2017 10-K
32 10-27-2017 09-30-2017 10-Q
33 07-28-2017 06-30-2017 10-Q
34 05-01-2017 03-31-2017 10-Q
35 02-21-2017 12-31-2016 10-K
36 10-28-2016 09-30-2016 10-Q
37 07-28-2016 06-30-2016 10-Q
38 04-29-2016 03-31-2016 10-Q
39 02-19-2016 12-31-2015 10-K
40 10-30-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
Eli Lilly's Oral Weight Loss Drug Shows Su...
10/15/2025 17:24:50

Orforglipron meets key endpoints in Phase 3 trials, showing A1C reduction, weight loss, and cardiovascular benefits for type 2 ...

eli-lillys-orforglipron-meets-all-endpoints-in-achieve-2-and-achieve-5-phase-3-trials-demonstrates-significant-a1c-reduction-and-weight-loss-in-type-2-diabetes
Eli Lilly's Orforglipron Meets All Endpoin...
10/15/2025 10:49:19

In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with dapagliflozin, meeting the primary endpointIn ACHIEV...

Core News & Articles
Recent Filing Shows That Sen. John Boozman...
10/13/2025 15:00:28

healthcare-opportunities-and-risks-collide-for-direxions-eli-lilly-focused-elil-elis-etfs
Healthcare Opportunities And Risks Collide...
10/13/2025 14:10:07

eli-lilly-to-support-whos-international-dementia-action-plan-under-signed-collaboration
Eli Lilly To Support WHO's International D...
10/13/2025 12:32:24

BERLIN, Oct. 13, 2025 /PRNewswire/ -- The WHO Foundation and Lilly have announced a collaboration to financially support the ai...

eli-lilly-to-present-new-data-across-oncology-portfolio-at-esmo-2025-highlighting-verzenio-and-emerging-cancer-therapies
Eli Lilly to Present New Data Across Oncol...
10/13/2025 10:47:43

Eli Lilly and Company (NYSE:LLY) today announced that new data from across its oncology portfolio and pipeline will be presente...

smart-money-is-betting-big-in-lly-options
Smart Money Is Betting Big In LLY Options
10/10/2025 20:01:08

bill-gates-and-paho-push-to-make-weight-loss-drugs-accessible-in-low-income-nations
Bill Gates And PAHO Push To Make Weight-Lo...
10/10/2025 17:58:32

Bill Gates and PAHO are working to make weight-loss drugs like Wegovy and Mounjaro more affordable for low-income countries.

direxions-qqqu-qqqd-etfs-foster-a-diversified-approach-to-magnificent-7-speculation
Direxion's QQQU, QQQD ETFs Foster A Divers...
10/09/2025 16:57:35

Core News & Articles
Recent Filing Shows That Rep. David Taylor...
10/08/2025 15:00:39

eli-lilly-to-rally-more-than-12-here-are-10-top-analyst-forecasts-for-wednesday
Eli Lilly To Rally More Than 12%? Here Are...
10/08/2025 14:04:25

guggenheim-maintains-buy-on-eli-lilly-raises-price-target-to-948
Guggenheim Maintains Buy on Eli Lilly, Rai...
10/08/2025 12:38:44

Guggenheim analyst Seamus Fernandez maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $875 to $948.

peter-marks-fda-vaccine-regulator-ousted-by-rfk-jr-joins-eli-lilly-marks-will-lead-molecule-discovery-and-infectious-diseases---stat-news
'Peter Marks, FDA Vaccine Regulator Ousted...
10/07/2025 19:02:07

https://www.statnews.com/2025/10/07/peter-marks-former-fda-vaccine-official-joins-eli-lilly/

looking-at-eli-lillys-recent-unusual-options-activity
Looking At Eli Lilly's Recent Unusual Opti...
10/07/2025 16:01:26

long-term-study-shows-sustained-remission-with-eli-lillys-ulcerative-colitis-drug
Long-Term Study Shows Sustained Remission ...
10/07/2025 15:05:46

Eli Lilly's four-year LUCENT-3 study shows Omvoh maintained high remission rates and a consistent safety profile in ulcerat...

eli-lillys-new-data-showed-omvoh-mirikizumab-mrkz-achieves-sustained-long-term-outcomes-through-four-years-in-ulcerative-colitis-patients
Eli Lilly's New Data Showed Omvoh (Mirikiz...
10/07/2025 10:49:49

Approximately 80% of Omvoh-treated patients in the LUCENT-3 study who achieved clinical remission at one year maintained long-t...

1000-invested-in-eli-lilly-10-years-ago-would-be-worth-this-much-today
$1000 Invested In Eli Lilly 10 Years Ago W...
10/06/2025 22:15:21

eli-lilly-eyes-india-for-manufacturing-plans-to-spend-1-billion
Eli Lilly Eyes India For Manufacturing, Pl...
10/06/2025 18:23:29

Eli Lilly plans over $1 billion investment in India to expand drug manufacturing, partnerships, and a new Hyderabad facility.

Core News & Articles
10 Health Care Stocks Whale Activity In To...
10/06/2025 17:35:26

eli-lilly-commits-over-1b-to-india-for-drug-manufacturing-and-a-new-quality-center-in-hyderabad
Eli Lilly Commits Over $1B To India For Dr...
10/06/2025 07:39:50

-Reuters

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION